SCHEMBL3635877

SCHEMBL3635877

CC(C)(C)c1n[nH]cc1CNc1cccc(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
GAA P10253 3/20 0.52
LMNA P02545 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
KDM4E B2RXH2 1/20 0.46
BRD4 O60885 1/20 0.46
IDH2 P48735 2/20 0.42
RXFP1 Q9HBX9 3/20 0.41
MEN1 O00255 1/20 0.41
XBP1 P17861 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SLC2A1 P11166 1/20 0.41
MAOB P27338 1/20 0.40
MAPK1 P28482 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
ABL1 P00519 1/20 0.39
EGFR P00533 1/20 0.39
CSF1R P07333 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3640671 0.85 TTBK1 (0.45) MAPTGAALMNAMAOBABL1
SCHEMBL3637940 0.85 MAPT (0.44) MAPTGAALMNASMN1; SMN2L3MBTL1
SCHEMBL3636189 0.84 MAPT (0.42) MAPTLMNABRD4CSF1R
SCHEMBL3641235 0.83 MAOB (0.43) MAPTGAALMNANPSR1MAOB
SCHEMBL3635913 0.83 MAPT (0.49) MAPTLMNASMN1; SMN2L3MBTL1KDM4E
SCHEMBL3634766 0.83 MAPT (0.41) MAPTGAALMNAMEN1KMT2A
SCHEMBL3633805 0.82 KDM4E (0.45) MAPTGAALMNASMN1; SMN2L3MBTL1
SCHEMBL3640679 0.81 MAOB (0.40) MAPTGAALMNAKDM4EMEN1
SCHEMBL3633513 0.81 MAPT (0.52) MAPTGAALMNAKDM4EMEN1
SCHEMBL3637577 0.80 LMNA (0.40) MAPTGAALMNASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 MAPT 572/4885GAA 2566/4885LMNA 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.